Losartan preserves glomerular basement membrane anionic charge sites in a rat model of nephropathy

Journal of Nephrology

Volumn 26, Issue 4, 2013, Pages 660-666

  Liu, Yan ^a   Zhou, Daoyuan ^a   Xiao, Xiao ^a   Qin, Danping ^a   Zhong, Xiaoshi ^a   Xiong, Xuan ^a   Inui, Kiyoko ^b   Yoshimura, Ashio ^b  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^b SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

Angiotensin II receptor blocker; Anionic site; Losartan; Proteinuria

Indexed keywords

ANION; CREATININE; LOSARTAN; NITROGEN; PROTEIN; SODIUM CHLORIDE; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL EXPANSION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; EPITHELIUM CELL; GLOMERULUS BASEMENT MEMBRANE; MALE; MESANGIUM CELL; NEPHROTIC SYNDROME; NONHUMAN; PROTEIN URINE LEVEL; RAT; SYSTOLIC BLOOD PRESSURE; TISSUE STRUCTURE; UREA NITROGEN BLOOD LEVEL;

EID: 84880117320     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000228     Document Type: Article

References (36)

1. Deckert T, Feldt-Rasmussen B, Djurup R, Deckert M. Glomerular size and charge selectivity in insulin-dependent diabetes mellitus. Kidney Int. 1988;33(1):100-106.
2. Bangstad HJ, Kofoed-Enevoldsen A, Dahl-Jørgensen K, Hanssen KF. Glomerular charge selectivity and the influence of improved blood glucose control in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia. 1992;35(12):1165-1169.
3. Deckert T, Kofoed-Enevoldsen A, Vidal P, Nørgaard K, Andreasen HB, Feldt-Rasmussen B. Sizeand charge selectivity of glomerular filtration in Type 1 (insulin-dependent) diabetic patients with and without albuminuria. Diabetologia. 1993;36(3):244-251.
4. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of anti-hypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993;118(2):129-138
5. Viberti GL, Mogensen CE, Groop LC, et al. European Micro-albuminuria Captopril Study Group. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA. 1994;271(4):275-279.
6. Hommel E, Parving HH, Mathiesen E, Edsberg B, Damkjaer Nielsen M, Giese J. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J (Clin Res Ed). 1986;293(6545):467-470.
7. Cooper ME, Allen TJ, Macmillan PA, Clarke BE, Jerums G, Doyle AE. Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat. Diabetologia. 1989;32(5):326-328.
8. Myers BD, Meyer TW. Angiotensin-converting enzyme inhibitors in the treatment of diabetic glomerulopathy. Nephron. 1990;55(Suppl 1):27-29.
9. Buter H, Hemmelder MH, van Paassen P, Navis G, de Zeeuw D, de Jong PE. Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night? Nephrol Dial Transplant. 1997;12(Suppl 2):53-56.
10. Reddi AS. Prevention of albuminuria by captopril in diabetic rats. Gen Pharmacol. 1991;22(2):323-328.
11. Reddi AS, Ramamurthi R, Miller M, Dhuper S, Lasker N. Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Biochem Med Metab Biol. 1991;45(1):119-131.
12. Hansen PM, Mathiesen ER, Kofoed-Enevoldsen A, Deckert T. Possible effect of angiotensin-converting enzyme inhibition on glomerular charge selectivity. J Diabetes Complications. 1995;9(3):158-162.
13. Deyneli O, Yavuz D, Velioglu A, et al. Effects of ACE inhibition and angiotensin II receptor blockade on glomerular basement membrane protein excretion and charge selectivity in type 2 diabetic patients. J Renin Angiotensin Aldosterone Syst. 2006;7(2):98-103.
14. Cotter J, Oliveira P, Cunha P, Polónia J. Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system. Rev Port Cardiol. 2008;27(11):1395-1404.
15. Omae K, Ogawa T, Nitta K. Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease. Heart Vessels. 2010;25(3):203-208.
16. Peters H, Border WA, Noble NA. Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis. Kidney Int. 2000;57(4):1493-1501.
17. Tarif N, Bakris GL. Angiotensin II receptor blockade and progression of nondiabetic-mediated renal disease. Kidney Int Suppl. 1997;63:S67-S70.
18. Amuchastegui SC, Azzollini N, Mister M, Pezzotta A, Perico N, Remuzzi G. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol. 1998;9(10):1948-1955.
19. Yavuz DG, Ersöz O, Kuçükkaya B, et al. The effect of losartan and captopril on glomerular basement membrane anionic charge in a diabetic rat model. J Hypertens. 1999;17(8):1217-1223.
20. Mayer G, Lafayette RA, Oliver J, Deen WM, Myers BD, Meyer TW. Effects of angiotensin II receptor blockade on remnant glomerular permselectivity. Kidney Int. 1993;43(2):346-353.
21. Yoshimura A, Ohno S, Nakano K, et al. Three-dimensional ultrastructure of anionic sites of the glomerular basement membrane by a quick-freezing and deep-etching method using a cationic tracer. Histochemistry. 1991;96(2):107-113.
22. Shinosaki T, Takagawa I, Sunagawa N, Yonetani Y, Kurihara H. Dual effects of lisinopril on puromycin aminonucleoside nephrosis in unilaterally nephrectomized rats. Jpn J Pharmacol. 1997;73(4):337-345.
23. Ryan GB, Karnovsky MJ. An ultrastructural study of the mechanisms of proteinuria in aminonucleoside nephrosis. Kidney Int. 1975;8(4):219-232.
24. Kanwar YS, Rosenzweig LJ. Altered glomerular permeability as a result of focal detachment of the visceral epithelium. Kidney Int. 1982;21(4):565-574.
25. Alpers CE, Hudkins KL, Gown AM, Johnson RJ. Enhanced expression of "muscle-specific" actin in glomerulonephritis. Kidney Int. 1992;41(5):1134-1142.
26. Schurer JW, Kalicharan D, Hoedemaeker PJ, Molenaar I. The use of polyethyleneimine for demonstration of anionic sites in basement membranes and collagen fibrils. J Histochem Cytochem. 1978;26(8):688-689.
27. Bradley GM, Benson ES. Examination of the urine. In: Davidson I, Henry JB, eds. Todd-Sanford clinical diagnosis by laboratory methods. Philadelphia, PA: Saunders; 1974:74.
28. Pippin JW, Brinkkoetter PT, Cormack-Aboud FC, et al. Inducible rodent models of acquired podocyte diseases. Am J Physiol Renal Physiol. 2009;296(2):F213-F229.
29. Michael AF, Blau E, Vernier RL. Glomerular polyanion. Alteration in aminonucleoside nephrosis. Lab Invest. 1970;23(6):649-657.
30. Kerjaschki D, Vernillo AT, Farquhar MG. Reduced sialylation of podocalyxin the major sialoprotein of the rat kidney glomerulus in aminonucleoside nephrosis. Am J Pathol. 1985;118(3):343-349.
31. Yavuz DG, Ersöz O, Kuçükkaya B, et al. The effect of losartan and captopril on glomerular basement membrane anionic charge in a diabetic rat model. J Hypertens. 1999;17(8):1217-1223.
32. Fukuda A, Fujimoto S, Iwatsubo S, Kawachi H, Kitamura K. Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome. Nephrology (Carlton). 2010;15(3):321-326.
33. Kashihara N, Haruna Y, Kondeti VK, Kanwar YS. Oxida-tive stress in diabetic nephropathy. Curr Med Chem. 2010; 17(34):4256-4269.
34. Harvey SJ, Miner JH. Revisiting the glomerular charge barrier in the molecular era. Curr Opin Nephrol Hypertens. 2008; 17(4):393-398.
35. Akira H. [Effects of human Cu, An-superoxide dismutase in aminonucleoside-nephrosis: evaluation of the morphologics and glomerular basement membrane anionic charge sites] [article in Japanese]. Japan Soc Nephrol. 1990;43:767-775.
36. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993;118(2):129-138.